Pancreatic Cancer
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer (ONTRAC)
A Phase II/III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer
Investigator: Andrew Coveler, MD; Conditions: Pancreatic Cancer; Status: Recruiting; Study ID: NCT01360853
A Phase II Study Induction Chemotherapy, Neoadjuvant Chemoradiotherapy, Surgical Resection and Adjuvant Chemotherapy for Patients with Locally Advanced, Resectable Pancreatic Adenocarcinoma
Investigator: Andrew Coveler, MD; Conditions: Pancreatic Cancer; Status: Recruiting; Study ID: NCT00609336
A Randomized Phase III Study of Weekly ABI-007 (Abraxane) plus Gemcitabine (Gemzar) versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas
Investigator: Sunil Hingorani, MD, PhD; Conditions: Pancreatic Cancer; Status: Closed; Study ID: NCT00844649
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
Investigator: Andrew Coveler, MD; Conditions: Pancreatic Neoplasms; Status: Closed; Study ID: NCT01166490
A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)
Investigator: Andrew Coveler, MD; Conditions: Neoplasms, Neoplasm Metastasis, Pancreatic Cancer; Status: Recruiting; Study ID: NCT01373164
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Investigator: Dr. Celestia S. Higano; Conditions: Advanced Solid Tumors; Status: Closed; Study ID: NCT00940225
Join Us On